Roche is starting a second late-stage trial of investigational Alzheimer’s drug crenezumab that it is developing with Swiss biotech AC Immune, shrugging off failures of similar drugs against the memory-robbing disease.
Roche’s new Phase III trial will recruit 750 patients with prodromal or mild Alzheimer’s disease, AC Immune said on Tuesday. An ongoing Phase III, 750-patient trial of crenezumab, which was developed by AC Immune, is due publish results in 2020.
Source: Reuters
Filed Under: Drug Discovery
